Cardioembolic stroke: a variety of causes and current approaches to its prevention
https://doi.org/10.14412/2074-2711-2013-2457
Abstract
Based on the data available in the literature and the results of their investigations, the authors give the present-day views of the role and place of cardiac diseases in the pathogenesis of cardioembolic stroke (CES). Among all causes of ischemic strokes, cardiogenic strokes are demonstrated to account for as high as 40%. Nonrheumatic atrial fibrillation, postinfarction changes, and rheumatic heart diseases are considered to be the leading causes of CES. Current recommendations for CES prevention are presented; the specific features of antithrombotic therapy are analyzed in detail.
About the Author
Lyudmila Aleksandrovna Geraskina
Neurology Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. <div><p>Суслина ЗА, Пирадов МА, редакторы. Инсульт: диагностика, лечение, профилактика. Москва: МЕДпресс-информ; 2008. 288 с. [Suslina ZA, Piradov MA, redaktory. Insul't: diagnostika, lechenie, profilaktika. Moscow: MEDpress-inform; 2008. 288 p.]</p><p>Petty GW, Brown RD, Whisnant JP et al. Ischemic stroke subtypes. A population-based study of functional outcome, survival and recurrence. Stroke. 2000;31(5):1062–8. DOI: http://dx.doi.org/10.1161/01.STR.31.5.1062.</p><p>Urbinelli R, Bolard P, Lemesle M et al. Stroke patterns in cardio-embolic infarction in a population-based study. Neurol Res. 2001;23(4):309–14.</p><p>DOI: http://dx.doi.org/10.1179/016164101101198668.</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Концепция и принципы кардионеврологии. В кн.: Очерки ангионеврологии. Суслина ЗА, редактор. Москва: Атмосфера; 2005. С. 108–21. [Fonyakin AV, Geraskina LA, Suslina ZA. Kontseptsiya i printsipy kardionevrologii. V kn.: Ocherki angionevrologii. Suslina ZA, editor. Moscow: Atmosfera; 2005. P. 108–21.]</p><p>Кузнецов АН, Виноградов ОИ, Рыбалко НВ. Современные подходы к антитромботической терапии у больных с кардиоэмболическим инсультом. Неврология, нейропсихиатрия и психосоматика. 2013;Cпецвыпуск 2:28–39. [Kuznetsov AN, Vinogradov OI, Rybalko NV. Current approaches to antithrombotic therapy in patients with cardioembolic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2013;Spetsvypusk 2:28–39. DOI: http://dx.doi.org/10.14412/2074-2711-2013-2356.]</p><p>Суслина ЗА, Фонякин АВ, Гераскина ЛА. Ишемический инсульт и сердце: от патогенеза к профилактике. Клиническая фармакология и терапия. 2003;(5):47–51. [Suslina ZA, Fonyakin AV, Geraskina LA. Ishemicheskiy insul't i serdtse: ot patogeneza k profilaktike. Klinicheskaya farmakologiya i terapiya. 2003;(5):47–51.]</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Стратификация причин кардиоэмболического инсульта. Неврологический журнал. 2002;(2):8–11. [Fonyakin AV, Geraskina LA, Suslina ZA. Stratifikatsiya prichin kardioembolicheskogo insul'ta. Nevrologicheskiy zhurnal. 2002;(2):8–11.]</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Сравнительная оценка постоянной и пароксизмальной фибрилляции предсердий в патогенезе кардиоцеребральной эмболии. Кардиология. 2002;(7):4–6. [Fonyakin AV, Geraskina LA, Suslina ZA. Sravnitel'naya otsenka postoyannoy i paroksizmal'noy fibrillyatsii predserdiy v patogeneze kardiotserebral'noy embolii. Kardiologiya. 2002;(7):4–6.]</p><p>Суслина ЗА, Гераскина ЛА, Фонякин АВ. Артериальная гипертония и инсульт: связь и перспективы профилактики. Атмосфера. Кардиология. 2001;(1):5–7. [Suslina ZA, Geraskina LA, Fonyakin AV. Arterial'naya gipertoniya i insul't: svyaz' i perspektivy profilaktiki. Atmosfera. Kardiologiya. 2001;(1):5–7.]</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Кардиальная патология при различных патогенетических подтипах ишемического инсульта. Клиническая медицина. 2002;(1):25–8. [Fonyakin AV, Geraskina LA, Suslina ZA. Kardial'naya patologiya pri razlichnykh patogeneticheskikh podtipakh ishemicheskogo insul'ta. Klinicheskaya meditsina. 2002;(1):25–8.]</p><p>Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Москва 2012. [Diagnostika i lechenie fibrillyatsii predserdiy. Rekomendatsii RKO, VNOA i ASSKh. Moscow, 2012.]</p><p>Mooe Th, Tienen D, Karp K, Eriksson P. Long-term follow-up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era. Heart. 1996;75(3):252–6. DOI: http://dx.doi.org/10.1136/hrt.75.3.252.</p><p>Hellerstein HK, Martin JW. Incidence of tromboembolic lesions accompanying myocardial infarction. Am Heart J. 1947;33(4):443–6. DOI: http://dx.doi.org/10.1016/0002-8703(47)90091-4.</p><p>Fukuda Y, Nakamura K. The incidence of tromboembolism and hemocoagulative background in patients with rheumatic heаrt disease. Jpn Circ J. 1984;48(1):599–604.</p><p>Mooe Th, Eriksson P, Stegmayer B. Ischemic stroke after acute myocardial infarction. Stroke. 1997;28(4):762–7. DOI: http://dx.doi.org/10.1161/01.STR.28.4.762.</p><p>Сторожаков ГИ, Гендлин ГЕ, Латышева ЕВ, Ганкова ЕВ. Больные с клапанными пороками сердца – лечение у терапевта до и после хирургической коррекции. Журнал сердечная недостаточность. 2002;(6):300–5. [Storozhakov GI, Gendlin GE, Latysheva EV, Gankova EV. Bol'nye s klapannymi porokami serdtsa – lechenie u terapevta do i posle khirurgicheskoy korrektsii. Zhurnal serdechnaya nedostatochnost'. 2002;(6):300–5.]</p><p>Суслина ЗА, Фонякин АВ, Чечеткин АО и др. Сравнительная клинико-инструментальная характеристика больных с открытым овальным окном при уточненном и криптогенном ишемическом инсульте. Кардиология. 2010;50(11):50–4. [Suslina ZA, Fonyakin AV, Chechetkin AO et al. Comparative Clinical and Anatomic Characteristic of Patients With Patent Foramen Ovale in Cryptogenic and Noncryptogenic Stroke. Kardiologiya. 2010;50(11):50–4.]</p><p>Meister SG, Grossman W, Dexter L, Dalen JE. Paradoxical embolism: Diagnosis during life. Am J Med. 1972;53(3):292–8. DOI: http://dx.doi.org/10.1016/0002-9343(72)90171-4.</p><p>Bassand JP, Bihr E, Becque O et al. Cerebral emboli of cardiac origin. J Neuroradiol. 1979;6(2):117–26.</p><p>Caplan LR. Brain embolism, revisited. Neurology. 1993;43(7):1281–7. DOI: http://dx.doi.org/10.1212/WNL.43.7.1281.</p><p>Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55(8):1172–9. DOI: http://dx.doi.org/10.1212/WNL.55.8.1172.</p><p>Drighil A, Mosalami H, Elbadaoui N et al. Patent foramen ovale: a new disease? Int J Cardiol. 2007;122(1):1–9. DOI: http://dx.doi.org/10.1016/j.ijcard.2006.12.028. Epub 2007 Mar 28.</p><p>Bogousslavsky J, Garazi S, Jeanrenaud X et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Neurology. 1996;46(5):1301–5. DOI: http://dx.doi.org/10.1212/WNL.46.5.1301.</p><p>Суслина ЗА, Фонякин АВ. Кардиальные аспекты патогенеза и профилактики ишемических инсультов. Креативная кардиология. 2007;(1–2):220–30. [Suslina ZA, Fonyakin AV. Kardial'nye aspekty patogeneza i profilaktiki ishemicheskikh insul'tov. Kreativnaya kardiologiya. 2007;(1–2):220–30.]</p><p>Kaste M. Statins in threatened stroke. Stroke. 2003;34(2):351–3. DOI: http://dx.doi.org/10.1161/01.STR.0000054260.05136.7D.</p><p>Amarenco P, Bogousslavsky J, Callahan A. 3rd et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59. DOI: http://dx.doi.org/10.1056/NEJMoa061894.</p><p>Furie KL, Kasner SE, Adams RJ et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. AHA/ASA Guideline. Stroke. 2011;42(1):227–76. DOI: http://dx.doi.org/10.1161/STR.0b013e3181f7d043.</p><p>European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457–507. DOI: http://dx.doi.org/10.1159/000131083.</p><p>Samsa GP, Matchar DB, Goldstein LB et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967–73. DOI: http://dx.doi.org/10.1001/archinte.160.7.967.</p><p>Baker W, Cios D, Sander S, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–52.</p><p>Гаврисюк ЕВ, Игнатьев ИВ, Сычев ДА, Маринин ВФ. Анализ применения непрямого антикоагулянта варфарина у пациентов с постоянной формой фибрилляции предсердий в поликлинических условиях. Клиническая фармакология и терапия. 2012;(1):42–7. [Gavrisyuk EV, Ignat'ev IV, Sychev DA, Marinin VF. Analiz primeneniya nepryamogo antikoagulyanta varfarina u patsientov s postoyannoy formoy fibrillyatsii predserdiy v poliklinicheskikh usloviyakh. Klinicheskaya farmakologiya i terapiya. 2012;(1):42–7.]</p><p>Bereznicki LRE, Peterson GM. New Antithrombotics for atrial fibrillation. Cardiovascular therapeutics. 2010;28(5):278–86. DOI: http://dx.doi.org/10.1111/j.1755-5922.2010.00209.x.</p><p>Connolly S, Progue J, Hart R et al.; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903–12. DOI: http://dx.doi.org/10.1016/S0140-6736(06)68845-4.</p><p>Meister SG, Grossman W, Dexter L, Dalen JE. Paradoxical embolism: Diagnosis during life. Am J Med. 1972;53(3):292–8. DOI: http://dx.doi.org/10.1016/0002-9343(72)90171-4.</p><p>Holmes DR, Reddy VY, Turi ZG et al.; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for the prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet. 2009;374(9689):534–42. DOI: http://dx.doi.org/10.1016/S0140-6736(09)61343-X.</p><p>Парфенов ВА, Вербицкая СВ. Новые возможности профилактики инсульта при фибрилляции предсердий. Неврология, нейропсихиатрия и психосоматика. 2012;(1):36–42. [Parfenov VA, Verbitskaya SV. New possibilities in the prevention of stroke in atrial fibrillation. Neurology, Neuropsychiatry, Psychosomatics. 2012;(1):36–42.]</p><p>Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. DOI: http://dx.doi.org/10.1056/NEJMoa0905561.</p><p>Oldgren J, Alings M, Darius H et al. Dabigatran versus warfarin in atrial fibrillation patients with low, moderate and high CHADS2 score: a RE-LY subgroup analysis. JACC. 2010;55:A1. DOI: http://dx.doi.org/10.1016/S0735-1097(10)60003-4.</p><p>Diener H-C, Connolly SJ, Ezekowitz MD et al.; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurology. 2010;9(12):1157–63. DOI: http://dx.doi.org/10.1016/S1474-4422(10)70274-X.</p><p>Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24(10):2757–65. DOI: http://dx.doi.org/10.1185/03007990802361499.</p><p>ROCKET AF Study Investigators. Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340–7.e1. DOI: 10.1016/j.ahj.2009.11.025.</p><p>Patel MR, Mahaffey KW, Gard J et al. Rivaroxaban vs Warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. DOI: http://dx.doi.org/10.1056/NEJMoa1009638.</p><p>Cucchiara BL, Kasner SE. Apixaban in Atrial Fibrillation: From Bleeding Cows to 21st Century Medicinal Chemistry. Stroke. 2011;42(8):2376–8. DOI: http://dx.doi.org/10.1161/STROKEAHA.111.619338.</p><p>Granger ChB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. DOI: http://dx.doi.org/10.1056/NEJMoa1107039.</p><p>Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–47. DOI: http://dx.doi.org/10.1093/eurheartj/ehs253.</p><p>Guyatt GH, Akl EA, Crowther M. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 2012;141 (2 Suppl):7S–47S.</p><p>Furie KL, Goldstein LB, Albers GW et al. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2012;43(12):3442–53. DOI: http://dx.doi.org/10.1161/STR.0b013e318266722a.</p><p>Granger ChB, Armaganijan LV. Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism? Circulation. 2012;125(1):159–64. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.111.031146.</p></div><br />
Review
For citations:
Geraskina LA. Cardioembolic stroke: a variety of causes and current approaches to its prevention. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(4):60-65. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2457
Views:
1191
Email this article 